Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Sentiment | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $9.68B | 107,351,594 | 29.07% | 70.93% | Net Buying | Net Selling | ||
| LQDA | LIQUIDIA CORP | $7.02B | 88,928,099 | 47.60% | 52.40% | Net Selling | Net Selling | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $41.76B | 133,512,573 | 82.21% | 17.79% | Net Selling | Net Buying | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $1.43B | 172,642,055 | 60.94% | 14.27% | Net Selling | Net Selling | ||
| KRYS | KRYSTAL BIOTECH INC | $11.06B | 29,479,756 | 79.66% | 20.34% | Net Selling | Net Selling | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $4.96B | 76,938,016 | 59.03% | 10.53% | Net Selling | Net Selling | ||
| HALO | HALOZYME THERAPEUTICS INC | $9.42B | 118,613,000 | 77.81% | 22.19% | Net Selling | Net Selling | ||
| VCEL | VERICEL CORP | $2.40B | 51,068,228 | 91.39% | 8.61% | Net Selling | Net Selling | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.40B | 193,284,438 | 95.00% | 1.82% | Net Selling | Net Selling | ||
| RPRX | ROYALTY PHARMA PLC | $33.27B | 575,832,204 | 62.11% | 17.27% | Net Selling | Net Selling | ||
| ADMA | ADMA BIOLOGICS INC | $2.07B | 231,772,715 | 79.04% | 20.96% | Net Selling | Net Buying | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $826.43M | 59,115,084 | 69.89% | 21.85% | Net Selling | Net Selling | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $15.28B | 62,742,820 | 29.89% | 70.11% | Net Selling | Net Selling | ||
| ASND | ASCENDIS PHARMA A | $17.05B | 62,111,595 | 99.19% | 0.81% | Net Selling | Net Selling | ||
| TGTX | TG THERAPEUTICS INC | $8.16B | 153,083,580 | 58.59% | 41.41% | Net Selling | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.16B | 57,892,676 | 78.99% | 21.01% | Net Selling | Net Selling | ||
| LGND | LIGAND PHARMACEUTICALS INC | $6.40B | 20,041,061 | 18.49% | 81.51% | Net Selling | Net Selling | ||
| TECH | BIO-TECHNE CORP | $11.09B | 156,568,751 | 97.83% | 2.17% | Net Selling | Net Selling | ||
| SPRO | SPERO THERAPEUTICS INC | $127.38M | 57,901,493 | 36.38% | 62.50% | Net Selling | Net Selling | ||
| EXEL | EXELIXIS INC | $14.04B | 251,355,083 | 94.86% | 5.14% | Net Selling | Net Selling | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $134.02B | 253,805,417 | 91.52% | 1.51% | Net Selling | Net Selling | ||
| NAGE | NIAGEN BIOSCIENCE INC | $273.18M | 79,644,327 | 20.68% | 79.32% | Net Buying | Net Buying | ||
| UTHR | UNITED THERAPEUTICS CORP | $23.60B | 42,446,733 | 86.75% | 13.25% | Net Selling | Net Buying | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $3.85B | 122,380,992 | 84.26% | 15.74% | Net Buying | |||
| REGN | REGENERON PHARMACEUTICALS INC | $68.59B | 104,839,032 | 68.59% | 31.41% | Net Selling | Net Selling | ||
| VCYT | VERACYTE INC | $4.55B | 79,792,647 | 67.25% | 32.75% | Net Selling | Net Selling | ||
| INCY | INCYTE CORP | $23.35B | 199,782,155 | 78.14% | 21.86% | Net Selling | Net Buying | ||
| SRPT | SAREPTA THERAPEUTICS INC | $2.04B | 105,576,222 | 77.22% | 22.78% | Net Selling | |||
| MDXG | MIMEDX GROUP INC | $588.34M | 148,945,731 | 48.14% | 51.86% | Net Buying | Net Buying |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.